# Topical Rapamycin for Fibrofolliculomas

> **NCT00928798** · PHASE3 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Birt-Hogg-Dubé Syndrome

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00928798
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-02
- **Final completion:** 2011-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928798, "Topical Rapamycin for Fibrofolliculomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00928798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*